These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 28374166)

  • 1. A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs.
    Urfer SR; Kaeberlein TL; Mailheau S; Bergman PJ; Creevy KE; Promislow DEL; Kaeberlein M
    Geroscience; 2017 Apr; 39(2):117-127. PubMed ID: 28374166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Trial of Rapamycin to Increase Longevity and Healthspan in Companion Animals: Navigating the Boundary Between Protections for Animal Research and Human Subjects Research.
    Taylor HA; Morales C; Johnson LM; Wilfond BS
    Am J Bioeth; 2018 Oct; 18(10):58-59. PubMed ID: 30339066
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.
    Kraig E; Linehan LA; Liang H; Romo TQ; Liu Q; Wu Y; Benavides AD; Curiel TJ; Javors MA; Musi N; Chiodo L; Koek W; Gelfond JAL; Kellogg DL
    Exp Gerontol; 2018 May; 105():53-69. PubMed ID: 29408453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial.
    Chung CL; Lawrence I; Hoffman M; Elgindi D; Nadhan K; Potnis M; Jin A; Sershon C; Binnebose R; Lorenzini A; Sell C
    Geroscience; 2019 Dec; 41(6):861-869. PubMed ID: 31761958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment.
    Quarles E; Basisty N; Chiao YA; Merrihew G; Gu H; Sweetwyne MT; Fredrickson J; Nguyen NH; Razumova M; Kooiker K; Moussavi-Harami F; Regnier M; Quarles C; MacCoss M; Rabinovitch PS
    Aging Cell; 2020 Feb; 19(2):e13086. PubMed ID: 31823466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asymptomatic heart valve dysfunction in healthy middle-aged companion dogs and its implications for cardiac aging.
    Urfer SR; Kaeberlein TL; Mailheau S; Bergman PJ; Creevy KE; Promislow DE; Kaeberlein M
    Geroscience; 2017 Feb; 39(1):43-50. PubMed ID: 28299636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial.
    Paoletti E; Amidone M; Cassottana P; Gherzi M; Marsano L; Cannella G
    Am J Kidney Dis; 2008 Aug; 52(2):324-30. PubMed ID: 18585837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Companion Dog as a Model for the Longevity Dividend.
    Creevy KE; Austad SN; Hoffman JM; O'Neill DG; Promislow DE
    Cold Spring Harb Perspect Med; 2016 Jan; 6(1):a026633. PubMed ID: 26729759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of oral pretreatment with metoprolol on left ventricular wall motion, infarct size, hemodynamics, and regional myocardial blood flow in anesthetized dogs during thrombotic coronary artery occlusion and reperfusion.
    Zmudka K; Dubiel J; Vanhaecke J; Flameng W; De Geest H
    Cardiovasc Drugs Ther; 1994 Jun; 8(3):479-87. PubMed ID: 7947365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open science study of ageing in companion dogs.
    Creevy KE; Akey JM; Kaeberlein M; Promislow DEL;
    Nature; 2022 Feb; 602(7895):51-57. PubMed ID: 35110758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A masked, placebo-controlled, randomized clinical trial evaluating safety and the effect on cardiac function of low-dose rapamycin in 17 healthy client-owned dogs.
    Barnett BG; Wesselowski SR; Gordon SG; Saunders AB; Promislow DEL; Schwartz SM; Chou L; Evans JB; Kaeberlein M; Creevy KE
    Front Vet Sci; 2023; 10():1168711. PubMed ID: 37275618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy.
    Saunders RN; Bicknell GR; Nicholson ML
    Transplantation; 2003 Mar; 75(6):772-80. PubMed ID: 12660500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echocardiography, a non-invasive method for the investigation of heart morphology and function in laboratory dogs: 2. Effects of minoxidil and quinidine on the left ventricle function.
    Hanton G; Lodola A
    Lab Anim; 1998 Apr; 32(2):183-90. PubMed ID: 9587901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin Versus Intermittent Feeding: Dissociable Effects on Physiological and Behavioral Outcomes When Initiated Early and Late in Life.
    Carter CS; Khamiss D; Matheny M; Toklu HZ; Kirichenko N; Strehler KY; Tümer N; Scarpace PJ; Morgan D
    J Gerontol A Biol Sci Med Sci; 2016 Jul; 71(7):866-75. PubMed ID: 25617380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Biology of Aging: Citizen Scientists and Their Pets as a Bridge Between Research on Model Organisms and Human Subjects.
    Kaeberlein M
    Vet Pathol; 2016 Mar; 53(2):291-8. PubMed ID: 26077786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers.
    Brattström C; Säwe J; Jansson B; Lönnebo A; Nordin J; Zimmerman JJ; Burke JT; Groth CG
    Ther Drug Monit; 2000 Oct; 22(5):537-44. PubMed ID: 11034258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical rapamycin combined with pulsed dye laser in the treatment of capillary vascular malformations in Sturge-Weber syndrome: phase II, randomized, double-blind, intraindividual placebo-controlled clinical trial.
    Marqués L; Núñez-Córdoba JM; Aguado L; Pretel M; Boixeda P; Nagore E; Baselga E; Redondo P
    J Am Acad Dermatol; 2015 Jan; 72(1):151-8.e1. PubMed ID: 25455610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).
    Pouleur AC; Anker S; Brito D; Brosteanu O; Hasenclever D; Casadei B; Edelmann F; Filippatos G; Gruson D; Ikonomidis I; Lhommel R; Mahmod M; Neubauer S; Persu A; Gerber BL; Piechnik S; Pieske B; Pieske-Kraigher E; Pinto F; Ponikowski P; Senni M; Trochu JN; Van Overstraeten N; Wachter R; Balligand JL
    ESC Heart Fail; 2018 Oct; 5(5):830-841. PubMed ID: 29932311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Left ventricular volume determined echocardiographically by assuming a constant left ventricular epicardial long-axis/short-axis dimension ratio throughout the cardiac cycle.
    Zile MR; Tanaka R; Lindroth JR; Spinale F; Carabello BA; Mirsky I
    J Am Coll Cardiol; 1992 Oct; 20(4):986-93. PubMed ID: 1388183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus-eluting stents in the canine cerebral vasculature: a prospective, randomized, blinded assessment of safety and vessel response.
    Levy EI; Hanel RA; Howington JU; Nemes B; Boulos AS; Tio FO; Paciorek AM; Amlani S; Kagan-Hallett KS; Fronckowiak MD; Guterman LR; Hopkins LN
    J Neurosurg; 2004 Apr; 100(4):688-94. PubMed ID: 15070124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.